Is My Cancer Different? A Personalized Medicine Campaign

December 29, 2011 | by

The Is My Cancer Different? campaign urges patients to ask their doctors a crucial question — is my cancer different? — and provides powerful information on why, when and how it could matter to their treatment choices.

Presented in video format and featuring cancer survivors, physicians, scientists, advocates and Ronnie Andrews, the president of Clarient, the personalized medicine campaign covers what indivdualized cancer treatment means, what makes a patient’s cancer different, treatment decisions, expert insights and more.

Is my cancer different?

A Brief History of The War on Cancer

November 1, 2011 | by

We’ve been fighting the war on cancer for forty years and although there has been a decrease in U.S. cancer deaths, the global burden of cancer has doubled over the last three decades [1]. Indeed, the leading cause of death in the world today is cancer, followed by heart disease and stroke [2,3]. Cancer also has the greatest economic impact from premature death and disability of all causes of death worldwide, costing $895 billion in 2008 [3]. That number is just the cost of loss of productivity; it doesn’t include the direct costs of treating cancer.

Man’s Best Friend: a Canine Biosensor for Cancer?

August 19, 2011 | by

Man’s best friend may someday turn out to be a physician’s tool for the detection of several types of cancer.

NBC Nightly News aired an intriguing story last night about dogs who have the ability to detect ovarian cancer [1]. The story referenced a new study published in the European Respiratory Journal that focused on canine scent detection for the diagnosis of lung cancer [2].

Health Highlights – July 18th, 2011

July 18, 2011 | by

Health Highlights is an occasionally recurring series focused on particularly interesting articles from credible sources of health and medical information that we follow & read. For a complete list of recommeded sources, see our links page.

Health Highlights

Biomarker Bulletin: July 5, 2011

July 5, 2011 | by

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

  • TCGA Study Brings Ovarian Cancer Patients Closer to Personalized Medicine

    In the June 30 issue of Nature, researchers from The Cancer Genome Atlas (TCGA) Research Network provide a large-scale integrative report on genetic mutations and pathways that distinguish the most common and aggressive type of ovarian cancer from other types of ovarian cancer as well as from other solid tumors. The disease is not defined by one or few cancer-driving genes but rather numerous mutations that individually occur in only a small number of cases. Given the degree of genomic disarray, the study results suggest that genomic structural variation is the driver of ovarian cancer. The findings may be helpful in guiding physicians to choose experimental treatments that are most likely to target molecular alterations effectively in patients with high-grade serous ovarian adenocarcinoma.

  • BGI Expanding Proteomics Services to Include Mass Spectrometry

    Earlier this month, Adam Bonislawski at GenomeWeb’s Proteomonitor reported that China-based BGI intends to expand its proteomics offerings and buy ~50 new mass spectrometers over the next two years. This diversification into clinical and drug-development services is a forward-thinking move for the genomics/bioinformatics giant and one that should be taken seriously by current proteomics service providers.

  • DHMRI Establishes Immune Monitoring Laboratory for Biomarker Discovery and Development

    Last week, the David H. Murdock Research Institute (DHMRI) announced that it acquired the Immune Tolerance Institute, Inc. (ITI) as a next step in its continued growth. The DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms as a major resource for a range of academic and industry partners undertaking both preclinical and clinical research.

  • NINDS to Fund Biomarker Clinical Study for Spinal Muscular Atrophy

    Earlier this month, the National Institute of Neurological Disorders and Stroke (NINDS) announced a funding opportunity and invited applications for a study of candidate biomarkers in Spinal Muscular Atrophy (SMA). The goals of the SMA biomarker validation study are to: (1) evaluate biomarkers and clinical outcomes longitudinally across a spectrum of SMA cases; (2) establish a clinical outcomes and biomarker database; and (3) contribute samples to the NINDS biorepository at the Coriell Institute for Medical Research to capture and share methods and pre-competitive data.

  • SciClips Launches Biomarker and Drug Discovery Protocols Database

    SciClips is an open innovation platform that enables scientists and researchers to collaborate and share research and ideas. Following up on a diagnostic and prognostic biomarker database released earlier this year, SciClips has launched a second database constisting of biomarker and drug discovery research protocols.